Table 4.
Disease | Phase | Vesicle cellular source | Route of administration | Isolation method | Modified (Y/N) | Status | Reference |
---|---|---|---|---|---|---|---|
Melanoma | I—open label | Autologous monocyte-derived dendritic cells | SC | UF/UC sucrose cushion | Y | Complete | Escudier et al. (92) |
Non-small cell lung cancer | I—open label | Autologous monocyte-derived dendritic cells | SC and intradermal | UF/UC sucrose cushion | Y | Complete | Morse et al. (93) |
Colon cancer | I—open label | Autologous ascites | SC | UC sucrose cushion | N | Complete | Dai et al. (95) |
Colon cancer | I—open label | Plant based | – | Not declared | Y | Ongoing | NCT01294072 |
Type I diabetes | I—open label | Umbilical cord blood (allogeneic) MSC | – | Not declared | N | Ongoing | NCT02138331 |
Non-small cell lung cancer | II—open label | Tumor cell | Pleural or peritoneal cavity | Not declared | Y | Complete | Besse et al. (96) |
Wound healing (Ulcer) | I—open label | Plasma (autologous) | – | Not declared | N | Enrolling | NCT02565264 |
MSC, mesenchymal stem/stromal cells; SC, subcutaneous; UF, ultrafiltration; UC, ultracentrifugation.
Adapted from Lener et al. (56).